Table 3.
Ongoing clinical trials in the first-line setting with nivolumab and ipilimumab
| NCT | Phase | Treatment |
|---|---|---|
| NCT03377023 | I | Nivolumab and ipilimumab and nintedanib |
| NCT02696993 | I/II | Nivolumab ± Ipilimumab and RT in brain M1 |
| NCT02983045 | I/II | Nivolumab + NKTR-214± ipilimumab |
| NCT03573947 | II | Nivolumab and ipilimumab and paclitaxel |
| NCT03425331 | II | Nivolumab and ipilimumab |
| NCT03001882 | II | Nivolumab and ipilimumab (CheckMate 592) |
| NCT03215706 | III | Nivolumab and ipilimumab and chemotherapy (CheckMate 9LA) |
| NCT03469960 | III | Nivolumab and ipilimumab (DICIPLE) |